Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 5, 2009

Ablynx and Novartis Ink One-Year Extension

  • Ablynx’ drug discovery and development alliance with Novartis has been extended for another year. The original deal was signed in December 2005, and an extension was made in December 2007.

    The agreement covers Nanobody-based therapeutics against disease targets that are difficult to address with conventional antibodies or their fragments. Novartis has exclusive rights to develop and commercialize any resulting products.

    Ablynx receives license fees and funding for research and development. The company is also eligible for milestone payments and royalties.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »